| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 15002144251 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:SDZ281-977
CAS:150779-71-8
Purity:99.64% Package:1mg/RMB 1080;5mg/RMB 2480;10mg/RMB 3970
|
| Company Name: |
Shanghai Yifei Biotechnology Co. , Ltd.
|
| Tel: |
021-65675885 18964387627 |
| Email: |
customer_service@efebio.com |
| Products Intro: |
Product Name:SDZ281-977
CAS:150779-71-8
Purity:95% Package:1mg;5mg;10mg
|
|
| | SDZ 281 977 Basic information |
| Product Name: | SDZ 281 977 | | Synonyms: | SDZ 281 977;SDZ-LAP 977;Benzoic acid, 5-[2-(2,5-dimethoxyphenyl)ethyl]-2-hydroxy-, methyl ester;SDZ281 977,SDZ-281-977,SDZ281977;Methyl 5-[2-(2,5-dimethoxyphenyl)ethyl]-2-hydroxybenzoate | | CAS: | 150779-71-8 | | MF: | C18H20O5 | | MW: | 316.35 | | EINECS: | | | Product Categories: | | | Mol File: | 150779-71-8.mol |  |
| | SDZ 281 977 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | form | Solid | | color | White to off-white |
| | SDZ 281 977 Usage And Synthesis |
| Uses | SDZ 281-977 is a derivative of the EGF receptor tyrosine kinase inhibitor Lavendustin A. | | in vivo | Nude mice bearing A431 human vulvar carcinomas receive intravenous injections of SDZ 281-977 (1-10 mg/kg) for 4 weeks. This treatment results in a dose-dependent inhibition of tumor growth. Orally administered SDZ 281-977 (30 mg/kg) induces a 54% inhibition of A431 tumor growth after 3 weeks of treatment. The above regimens are well tolerated. No significant change in body weight occurred during treatment[1]. | | References | [1] Cammisuli S, et al. SDZ 281-977: a modified partial structure of lavendustin A that exerts potent and selective antiproliferative activities in vitro and in vivo. Int J Cancer. 1996 Jan 26;65(3):351-9. DOI:10.1002/(SICI)1097-0215(19960126)65:33.0.CO;2-D |
| | SDZ 281 977 Preparation Products And Raw materials |
|